340B

Clinical Insights: April 27, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Indication/Dosage/Formulation Approval Veklury® (remdesivir) Injection – New Expanded Indication – April 25, 2022 – Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration…

Read More...

Clinical Insights: April 20, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Indication/Dosage/Formulation Approval No new update. New/Updated Drug Shortage April 18, 2022 Chlordiazepoxide Hydrochloride Capsules (Currently in Shortage) Digoxin Injection (Currently in Shortage) Disopyramide Phosphate (Norpace)…

Read More...

Clinical Insights: April 6, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Tlando™ (testosterone) Capsules – New Drug Approval – March 28, 2022 – Antares Pharma, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration granted final…

Read More...

Clinical Insights: March 30, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) and Locametz® (gallium Ga 68 gozetotide – New Drug Approval and New Diagnostic Approval – March 23, 2022 – The Food and Drug…

Read More...

Clinical Insights: March 23, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Ztalmy® (ganaxolone) Oral Suspension – New Drug Approval – March 18, 2022 – FDA has approved Ztalmy® (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder…

Read More...

Clinical Insights: March 15, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Lynparza® (Olaparib) Tablets – New Drug Approval – March 11, 2022 –  The Food and Drug Administration approved olaparib (Lynparza®, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult…

Read More...

Clinical Insights: March 9, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Carvykti™ (ciltacabtagene autoleucel) – New Orphan Drug Approval – February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA)…

Read More...

Clinical Insights: March 1, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval NephroScan™ (technetium Tc 99m succimer) Injection Kit – New Diagnostic Approval – February 22, 2022 – Theragnostics announces that NephroScan™, its radiodiagnostic imaging drug used as an aid for…

Read More...

Clinical Insights: February 23, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Pyrukynd® (mitapivat) Tablets – New Drug Approval – February 17, 2022 – FDA has approved Pyrukynd® (mitapivat) tablets to treat hemolytic anemia (a disorder in which red blood cells…

Read More...

Connect with RxStrategies at the 340B Coalition Winter Conference

The 2020 340B Coalition Winter Conference is near! RxStrategies is a proud Pinnacle Level sponsor of this great event, where attendees will receive the latest actionable intelligence in areas such as 340B implementation and operations, compliance, contract pharmacy, inventory management, and specialty pharmacy. The conference will take place in San Diego, CA, February 10 –…

Read More...

Clinical Insights: September 30, 2019

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Jynneos™ (smallpox and monkeypox vaccine, live, nonreplicating) – New Vaccine Approval – September 24, 2019 – The U.S. Food and Drug Administration announced the approval…

Read More...

Let’s Connect: APHCA Annual Conference and Expo

RxStrategies is proud to be a Platinum Presenting Sponsor of Alabama Primary Health Care Association’s (APHCA) Annual Bootcamp, Conference and Expo. The event is the State’s largest annual gathering of community health systems, providers and partners from across the community of care. This year’s annual event, Taking Point, will be held on October 1-3, 2019 at…

Read More...